Abstract:In recent years, the U.S. Food and Drug Administration (FDA) has approved Chimeric Antigen Receptor (CAR)-T cell therapy as a novel approach to treating hematological diseases, including multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukemia. Using the patient's genetically altered T-cells, this novel strategy precisely targets antigens linked to cancer. Even with the encouraging outcomes of using bi-specific chimeric antigen receptors to stop tumor antigen evasion, difficulties still arise, especially when dealing with solid tumors. There are several challenges because of the intricate interactions among many elements in the tumor microenvironment, such as immunosuppression, hypoxia, decreased T-cell infiltration, elevated reactive oxygen species, and the erratic nature of tumor-associated antigens. This study examines current efforts to find reliable tumor-associated antigens in an attempt to address issues impeding the efficacy of CAR-T treatment. The fundamental objective is to create CAR-T cells that are economical while being adapted to the distinct characteristics of the tumor microenvironment. By means of a comprehensive analysis of the course of the therapy, the study explores its potential therapeutic uses for a range of tumor types, including solid and hematological malignancies. This work not only sheds light on the enormous obstacles to obtaining precision medicine in cancer treatment, but it also advances our knowledge of the promise that the specific therapy has. The presented results open the door for future developments in the field and provide a nuanced viewpoint on the revolutionary role that the treatment has played in the contemporary cancer scene.

Target selection for CAR-T therapy

Target Selection of CAR T Cell Therapy in Accordance with the TME for Solid Tumors.

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19

Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Current progress in CAR-T cell therapy for tumor treatment

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens

Hurdles of CAR-T Cell-Based Cancer Immunotherapy Directed Against Solid Tumors.

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Current Clinical Application of the CAR-T Cell Therapy

Bright future or blind alley? CAR-T cell therapy for solid tumors

Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment

CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment

A long way to the battlefront: CAR T cell therapy against solid cancers.

Tumor Buster - Where Will the CAR-T Cell Therapy ‘missile’ Go?

Research Progress of Multi-target CAR-T Cell Therapy for Cancer